New FDA Biotech Office
نویسندگان
چکیده
منابع مشابه
Can biotech deliver new antibiotics?
The evolution of support for the discovery and development of antibacterial (or antibiotic) agents from the larger pharmaceutical companies to the entrepreneur-like small biotechnology companies has been an experiment in the making for the past 15 years. The word 'experiment' is precisely chosen as the outcome is not certain. Many of the antibiotic biotech organizations that were most likely to...
متن کاملThe FDA and new safety warnings.
Comment. The majority of primary health care providers agree that their patients should reduce sodium intake; report providing specific advice in line with recommended strategies; and counsel patients with prehypertension, hypertension, or chronic kidney disease to consume less salt. In contrast to 2010 dietary guidelines, a minority of health care providers report counseling patients with diab...
متن کاملFDA approves new drug to treat dementia.
Actavis and Adamas Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration has approved the New Drug Application for NamzaricTM for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on memantine hydrochloride and donepezil hydrochloride. Namzaric will be available in two dosage strengths: 28/10 mg (memantine extended release/donepezi...
متن کاملWill biotech venture thrive in the new climate in Japan?
I recently kicked off a biotech venture company in Japan. This is something unusual to see here, as there are few university-based startup companies in this country. According to one statistic, the number of biotech venture companies in Japan is now around 60, very many fewer than in the US which has around 1,700. Only ten new companies started last year and most of them were backed by establis...
متن کاملUniversity opposition to unfettered research: a new bedfellow for biotech?
This Article examines university opposition to a proposed statutory exemption to infringement liability for basic genetic research and patient care. Gene patenting has allowed patentees to bar basic genetic research, slowing the progress of developing and administering diagnostics and gene-targeting therapeutics. Debates over the merits of gene patents have been heated, most recently leading to...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Biotechnology
سال: 1989
ISSN: 1087-0156,1546-1696
DOI: 10.1038/nbt1289-1228b